Valerie Yang: How should patients with advanced mucosal melanoma be treated?

Valerie Yang, Consultant Medical Oncologist, National Cancer Centre Singapore, shared a post on LinkedIn:

“In Singapore and in Asia, the prototypical immune-responsive cutaneous melanomas are not as common as in the West. Our melanomas include the rarer Asian subtypes, such as mucosal melanomas. They are typically underrepresented in global clinical trials and have no standards of care.

As oncologists who face this challenging disease, we ask – how should patients with advanced mucosal melanoma be treated? Is combination anti-PD1+CTLA4 immunotherapy really needed? Are other modalities like KIT or VEGF inhibition or radiation effective? We present a meta-analysis of 2,833 individual patients from 35 studies which suggests that anti-PD1 should be standard of care.”

Effectiveness of immune checkpoint inhibitors and other treatment modalities in patients with advanced mucosal melanomas: a systematic review and individual patient data meta-analysis

Authors: Andrea York Tiang Teo, Chun En Yau, Chen Ee Low, Jarett Vanz-Brian Pereira, Julia Yu Xin Ng, Tse Kiat Soong, Jack Yu Tung Lo and Valerie Shiwen Yang.

Source: Valerie Yang/LinkedIn